Despite winning an FDA approval in 2023 and gaining clarity in May on the regulatory path forward for its Type 1 diabetes prospect sotagliflozin, Lexicon Pharmaceuticals hasn’t had an easy go of it in ...
Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating ...
Within the iShares Nasdaq Biotechnology ETF (IBB), the biotechnology and pharmaceutical subgroups have a combined weight of ~97.5% of IBB’s portfolio. The moving average provides investors with a ...
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...
Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. The biotech focused on low-dose results from its latest phase 2 trial, rather than the overall ...
March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...
During the last three months, 6 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback